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Abstract 24 
Background/Objectives: Reduced appetite is a recognised physiological symptom in survivors of 25 
critical illness.  Whilst reduced appetite has been reported by patients after ICU,  quantification 26 
using visual analogue scales has not been previously performed, and follow-up duration has been 27 
limited.  We aimed to describe appetite scores in ICU survivors during the first three months post 28 
ICU discharge and explore association with systemic inflammation. 29 
Subjects/Methods: Secondary analysis of data collected in a complex rehabilitation intervention 30 
trial (RECOVER).  A subgroup of 193 patients provided specific consent for inclusion in the blood 31 
sampling sub-study during consent for the main study.  We studied appetite using a visual analogue 32 
scale (VAS); serum C-reactive protein (CRP); interleukin 1β and 6 (IL-1β and IL-6); and hand-grip 33 
strength (HGS). 34 
Results: Median (IQR) score on 0-10 appetite visual analogue scale was 4.3 (2.0-6.5) 1 week after 35 
ICU discharge, improving to 7.1 (4.6-8.9) by 3 months (mean difference 1.7 (0.9-2.4) p<0.01).  36 
Number of days spent in an acute hospital following an intensive care stay was associated with 37 
poorer appetite scores (p=0.03). CRP concentration and appetite were significantly associated at 1 38 
week after ICU discharge (p=0.01), but not at 3 months after ICU discharge (p=0.67). 39 
Conclusions:  ICU survivors experience reduced appetite during the acute recovery phase of 40 
critical illness that could impact on nutritional recovery and this was associated with CRP 41 
concentration 1 week after ICU discharge. 42 
 43 
Introduction 44 
Survivors of critical illness suffer physical weakness caused by acquired neuromuscular deficits 45 
often superimposed on pre-existing frailty (1).  Skeletal muscle loss is is part of this deficit and 46 
occurs early during critical illness (2,3).  Efforts to improve physical outcomes have so far been 47 
unsuccessful (4-10).  Optimising nutritional state during the recovery phase of critical illness is an 48 
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integral part of physical rehabilitation and reduced appetite at this time may impact on nutritional 49 
intake.  50 
Malnutrition is observed frequently in ICU patients with many (43%) beng clinically malnourished 51 
on admission (11).  Nutritional status declines during critical illness, and on the post-ICU ward 52 
(11,12).  Malnutrition is associated with muscle loss and functional decline (13-16). Optimal nutritional 53 
support for ICU survivors is therefore crucial to post-ICU recovery (17).    54 
 55 
During the early recovery period (during the first 7 days after tracheal extubation), patients do not 56 
achieve their calorific targets, and consume fewer than 50% of their estimated protein requirements 57 
(18).  ICU survivors also fail to meet their nutritional targets up to three months after ICU discharge 58 
(19).   Poor appetite during this period has been shown to be an important barrier to eating (18).  59 
 60 
The mechanisms underlying appetite suppression in survivors of critical illness remain unclear.  61 
Ghrelin, a 28 amino-acid peptide released from the stomach is an important regulatory hormone 62 
controlling appetite and metabolism in humans (20). There is conflicting evidence regarding serum 63 
ghrelin concentrations in critically ill patients with some studies reporting decreased circulating 64 
levels of ghrelin and others higher ghrelin concentrations compared with healthy controls (21,12).   65 
Pro-inflammatory cytokines, have a central depressive effect on both food intake (22) and appetite 66 
(23).  A recent inflammatory biomarker study showed that there was a high prevalence of systemic 67 
inflammation after ICU (70% at ICU discharge and 30% at 3 months) suggesting a prolonged 68 
inflammatory response (24).  We hypothesise that inflammation during recovery from critical illness 69 
suppresses appetite, and could have an important impact on physical outcome.    70 
 71 
In this analysis we aimed to study the longitudinal course of appetite scores after ICU discharge.  A 72 
secondary aim was to explore the relationship between appetite and biochemical markers of 73 
systemic inflammation. 74 
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 76 
Materials/Subjects and Methods 77 
Ethics 78 
This study was approved by the Scotland ‘A’ research ethics committee and conducted in 79 
accordance with the Helsinki Declaration of 1975 as revised in 1983.     80 
 81 
Patients 82 
The RECOVER study was a randomised trial of increased hospital-based physical rehabilitation 83 
versus standard ward care for survivors of critical illness.  The trial protocol and  main results have 84 
been previously published (4, 25).  85 
 86 
Briefly, patients were eligible for RECOVER if they were adult survivors of critical illness, were 87 
ventilated for greater than 48 hours and were deemed fit for ICU discharge by the treating 88 
physician.  Exclusion criteria included a primary neurological diagnosis, receipt of palliative care, 89 
receipt of home ventilation or under 18 years of age.   90 
 91 
At recruitment into the study patients were randomised into either the control or intervention group.  92 
Both groups received existing ward-based physiotherapy, dietetics, occupational and 93 
speech/language therapy until hospital discharge. The intervention patients received enhanced 94 
hospital-based physical rehabilitation that increased the frequency and intensity of rehabilitation 95 
during their ward stay.  This was delivered by a generic rehabilitation assistant (GRA) with 96 
nutritional interventions  including support and encouragement to eat and greater attention to 97 
monitoring of nutritional intake. 98 
 99 
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The between-group comparison of outcomes in the trial found no clinically or statistically 100 
significant differences in measures of physical function, health-related quality of life (HRQoL), 101 
psychological morbidity or self-reported symptoms (25), and therefore the patients were treated as a 102 
single group for the purpose of this analysis. 103 
 104 
A subgroup of 193 patients provided specific consent for inclusion in the blood sampling sub-study 105 
during consent for the main study. 106 
 107 
Measurements 108 
Appetite was assessed in study participants 1 week after study entry (equating to 1 week after ICU 109 
discharge), weekly until hospital discharge, and again at a follow up appointment 3 months after 110 
study entry.  In those patients discharged from hospital during the follow up period i.e. those that 111 
did not die in hospital (death in hospital = 4 patients) or were not still in hospital 3 months after 112 
enrolment (inpatient at 3 months = 12 patients), appetite scores were reported at hospital discharge.   113 
 114 
Appetite assessment was conducted using a 10 centimetre visual analogue scale (VAS).  At each 115 
end of the line words described the minimum and maximum extremes of the characteristic being 116 
measured with the low end to the left on a horizontal scale (26).  Individuals were asked to mark on 117 
the line at the point they felt indicated how they were currently feeling.  The score was determined 118 
by measuring the distance from the left hand end on a horizontal scale to the point marked by the 119 
individual (27).  VAS are a reliable and reproducible tool for assessing appetite (28), however it has 120 
not been validated in the post ICU patient population.  121 
 122 
To explore the medium-term nutritional consequences of appetite suppression on nutritional status, 123 
we measured hand-grip strength 3 months after study enrolment (29). 124 
 125 
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We measured the serum concentration of C-reactive protein (CRP), interleukin 6 (IL-6) and 126 
interleukin 1β (IL-1β) by ELISA (R and D systems) to detect the presence of on-going 127 
inflammation during the recovery phase of critical illness.  For this study, blood was analysed at 128 
two time points corresponding to the first appetite assessment and the 3 month follow up 129 
assessment. 130 
 131 
Statistical Analysis 132 
VAS appetite scores had a non-parametric distribution and are presented as medians with 133 
interquartile ranges for each time point.  Paired differences between baseline and follow up samples 134 
were normal in distribution and a t-test was applied to compare this difference to zero.  135 
 136 
To explore the association between inflammation and appetite, we calculated Kendall’s tau 137 
correlation co-efficient for the VAS appetite score and inflammatory biomarkers at the time of the 138 
first appetite assessment (1 week after study entry), and follow up (3 months after study entry).   139 
 140 
To explore the medium-term functional consequences of appetite suppression we tested the 141 
association between appetite score at hospital discharge, and hand grip strength at the 3 month 142 
follow up stage using the Spearman’s rho correlation co-efficient.  In addition, the sample was 143 
divided into 2 groups above and below the median appetite VAS score. The mean hand grip 144 
strength in each of these groups was compared using an independent samples t-test.  To take into 145 
account the effects of age and gender on hand grip strength, percentage predicted hand-grip strength 146 
was calculated using population norms derived from a previous study (30) and the above analysis 147 
repeated. 148 
 149 
The correlation coefficients used in the analysis were selected on the basis of distributions and can 150 
be justified (data not shown). 151 
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 152 
Results 153 
Patients and completeness of data 154 
240 patients were recruited to the RECOVER study between December 2010 and January 2013.  155 
228 (95%) were followed up to 3 months.  The baseline characteristics of the cohort are described 156 
in Table 1.  At the time of first assessment (1 week after study entry), 152 patients had appetite 157 
VAS score measured.  At final assessment, 188 patients had appetite VAS score measured.   158 
 159 
193 patients (80%) gave consent for inclusion in the blood sampling sub-study.  At the first 160 
assessment (1 week after study entry), 109 patients had CRP, IL-1β, and IL-6 measured.  At the 161 
final assessment, 123 patients had CRP measured, 120 patients had IL-6 and 120 patients had IL-1β 162 
measured. 163 
 164 
Appetite 165 
Appetite scores at each time point are presented in Figure 1.  Median VAS appetite score was low 166 
(below 5cm) at each time point until after ICU discharge. There was an improvement in appetite 167 
from a median (IQR) of 4.3 (2.0-6.5) to 7.1 (4.6-8.9) during the first 3 months. The mean (95% CI) 168 
for this difference was 1.7 (0.9 – 2.4) (p=0.000).   169 
 170 
To illustrate change in appetite over time, patients available for assessment at both baseline and 3 171 
months (n=130) were divided into 4 groups according to their appetite scores. The percentage of 172 
patients within each group at each time point are illustrated in Figure 2.   173 
 174 
Post-hoc analysis 175 
For patients staying in hospital for many weeks after ICU discharge appetite scores appeared to be 176 
particularly low (Figure 1).  To explore this further, mean appetite scores were calculated for each 177 
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patient during their post-ICU hospital stay and the correlation between the number of days in 178 
hospital after enrolment in RECOVER, and mean appetite score during hospitalisation was 179 
calculated.   Spearman’s rho was -0.231 (p=0.030) for this correlation suggesting that patients who 180 
spent longer periods in the acute hospital post ICU discharge was associated with poor appetite.  To 181 
illustrate this point, Figure 3 shows the appetite scores in the weeks following ICU discharge for 182 
patients who spent ≤5 weeks in hospital (n=130) versus those spending >5 weeks in hospital 183 
(n=30).  Note those patients discharged home prior to 1 week after enrolment had no appetite score 184 
measured in hospital and were not considered. 185 
 186 
In the patients that were discharged from hospital alive (n=141), the median (IQR) appetite VAS 187 
was 5.0 (3.0-8.0) at hospital discharge. 188 
 189 
Appetite and functional outcome  190 
There was no significant association between appetite at hospital discharge and predicted handgrip 191 
strength at the 3-month follow up point (Pearson Correlation 0.032; p=0.756). 192 
 193 
Appetite and inflammation 194 
A summary of the analysis is given in Table 2.  There was a significant correlation between CRP 195 
concentration and appetite VAS at the first assessment point (Kendall’s tau B -0.159 (p=0.018).  At 196 
the 3-month assessment, the correlation was not significant (Kendall’s tau B -0.026; p=0.67).  There 197 
was no significant association between IL-6 at first or follow up assessment.  IL1- β was 198 
undetectable in the majority of patients throughout the study and therefore formal tests of 199 
correlation were not conducted for this molecule.  200 
 201 
Discussion 202 
Appetite suppression 203 
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In this paper we confirm the findings of previous studies that identified appetite suppression to be a 204 
significant symptom in the early days of post-ICU recovery.  In addition, we have shown that loss 205 
of appetite is sustained during the period of post-ICU hospitalisation.     206 
 207 
In contrast to previous studies, we have also identified appetite suppression at the point of hospital 208 
discharge, a crucial transition in the nutritional care of ICU survivors.  Although hospital discharge 209 
defines the point where patients are physically able to cope with some activities of daily living, it is 210 
also the point when the acute care rehabilitation, including dietetic input ceases (31) and a time when 211 
even modest dietetic input can lead to nutritional and functional gains (32).  212 
 213 
Nutritional care is a key component of physical recovery after critical illness (17).   Traditional 214 
approaches to nutritional rehabilitation focus on supplementing hospital food to achieve nutritional 215 
targets, approaches that fail when appetite is suppressed and patients have little inclination or 216 
motivation to eat (12).  With the knowledge that ICU patients suffer sustained appetite suppression, 217 
efforts to improve post-ICU nutritional status must now focus on efforts to improve or circumvent 218 
appetite suppression.  In addition, greater efforts must be made to equip patients with information 219 
and advice to help them recognise and overcome this common and limiting symptomatology after 220 
hospital discharge. 221 
 222 
Pharmacological modification of appetite in these patients may be possible in the future.  Recent 223 
animal studies have suggested the potential role of ghrelin as a future potential therapeutic utility to 224 
stimulate feeding and growth hormone secretion by promoting gastric peristalsis and generating 225 
hunger sensations (33,34) In healthy humans, higher levels of ghrelin are seen during periods of 226 
fasting and vice versa after meal, which are associated with elevated insulin and low glucose levels 227 
(20,33,36).  There is a paucity of data with regard to the relationship between appetite and calorie 228 
intake with ghrelin levels after ICU discharge. 229 
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 230 
More practical measures to promote nutritional intake in patients with poor appetite include offering 231 
small frequent meals and the provision of energy dense foods (37).  Previous work has shown that 232 
providing three meals a day is seen as a deterrent to post ICU patients with small appetites who find 233 
larger meals off-putting (31).   234 
 235 
The social nature of eating is an important contributor to increased food intake with energy intakes 236 
increased by 36% in patients using a dining room compared to those who ate beside their bed (38).  237 
However, the application of this solution may require some creativity in a post-ICU cohort, many of 238 
whom may be nursed in isolation for infection control reasons or experience reduced mobility due 239 
to critical illness related muscle weakness. 240 
 241 
The effect of exercise on appetite has been widely studied with a body of evidence suggesting that 242 
an acute bout of exercise does not result in an increase in appetite and food intake (39-41).  It is now 243 
widely reported that vigorous exercise can transiently suppress appetite (42) however this response 244 
is short lived and is not observed in low or moderate intensity exercise (43).  In the RECOVER 245 
study (25) there was no difference in appetite at 3 months between the intervention and control 246 
groups, but we were unable to assess the impact of exercise frequency or intensity on appetite. 247 
 248 
Critical illness is characterised by systemic inflammation, a defensive response carefully regulated 249 
by circulating inflammatory cytokines.  In many patients inflammation is sustained beyond ICU 250 
discharge (24).  Previous studies have shown a possible role for inflammation in appetite 251 
suppression in non-critically ill populations.  Patients undergoing haemodialysis have appetite 252 
suppression in association with higher concentrations of pro-inflammatory cytokines (44).  Poor 253 
appetite was also linked to increased mortality, higher rates of hospitalisation and reduced quality of 254 
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life.  Similar findings have been shown in patients with advanced cancer where increased levels of 255 
inflammation were associated with a number of symptoms including pain, fatigue and anorexia (45).   256 
 257 
One of the best-described pro-inflammatory cytokines is interleukin 1β, which is known to exert a 258 
profound depression of appetite mechanisms (23).  Unfortunately, in our study IL1- β was 259 
undetectable in the majority of patients, therefore we were unable to include this molecule in our 260 
analysis. Tumor-necrosis factor-α (TNF- α) and interleukin-6 are the other pro-inflammatory 261 
cytokines known to induce anorexia (46).  The mechanisms by which these cytokines affect the 262 
central nervous system controls of food intake are not fully understood (22).  Through signalling in 263 
the hypothalamus, the pro-inflammatory cytokines activate neuro-pathways that repress the desire 264 
for food.  These cytokines also activate signalling from the autonomic nervous system modulating 265 
gastric motility and emptying.  Additionally the cytokines stimulate the release of hormones that 266 
suppress food intake such as leptin and insulin (47). 267 
 268 
In our study, we found that patients with higher C-reactive protein concentrations soon after ICU 269 
discharge had poorer appetite scores suggesting a potential role for systemic inflammation in post 270 
intensive care appetite suppression, but found no association between CRP and appetite at 3 months 271 
or IL-6 and appetite at either 1 week or 3 months. 272 
 273 
In previous work, we explored risk factors for appetite at 3, 6, and 12 month time points after ICU 274 
and found illness severity to be insignificant when compared to pre-ICU factors (48).  Whether this 275 
is the case for earlier time points remains unknown, but certainly the association with pro-276 
inflammatory mediators suggests that ongoing pathology may play a role. 277 
 278 
There are several weaknesses of the study.  First, this is a post-hoc analysis and the original 279 
RECOVER trial was not powered to detect the correlations explored.  Second, our measure of 280 
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appetite has not been used in this cohort previously and we have no control group to compare our 281 
patients to.  It is therefore difficult to determine whether the appetite scores noted in our results 282 
could be considered normal, poor, or good.  Third, we did not measure oral intake or calorific 283 
consumption in this study so could not assess the impact of appetite suppression on eating 284 
behaviour.  Fourth, the cohort is representative of a ventilated mixed medical/surgical cohort, but it 285 
is worth noting that a significant proportion had a GI diagnosis, potentially resulting in more severe 286 
appetite suppression, depending on the comparator population. 287 
 288 
Conclusions 289 
ICU survivors experience a supressed appetite during the acute recovery phase of critical illness. 290 
Inflammation was found to be associated with appetite at time points close to ICU discharge 291 
suggesting possible modifying effect of systemic inflammation on appetite in the early post-ICU 292 
period, a crucial time for nutritional intervention.  Nutritional management of ICU survivors should 293 
include ways to maximise intake in order to help circumvent the suppression of appetite 294 
encountered by this patient group, and modification of the inflammatory response may be a future 295 
avenue for investigation. 296 
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Table 1: Participant characteristics at randomization. 429 
Table 2: Kendall’s tau correlation coefficients of inflammatory biomarkers with appetite visual 430 
analogue scores. 431 
 432 
Figure 1: Appetite scores by week after ICU discharge.  Grey shading indicates the number of 433 
patients assessed at each time.  Only patients remaining in hospital had appetite VAS recorded 434 
which explains the decline in n number but we aimed to assess all patients surviving to 3 months. 435 
 436 
Figure 2: For patients with complete data, change in appetite score category between baseline and 3 437 
months (n=130 patients).   438 
 439 
Figure 3: Appetite scores after ICU discharge (median (IQR)).  Square markers denote patients 440 
staying in hospital up to 5 weeks after ICU discharge (n=130).  Round markers denote patients 441 
staying in hospital greater than 5 weeks after ICU discharge (n=30). 442 
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re
from
 RECOVER cohort 
(n=240) 
Male N (%) 137 (57) 
Age (median (1st ;3rd quartiles)) 62 (52, 70) 
Days of ventilation in ICU (median (1st ;3rd quartiles)) 8 (5,15) 
APACHE II score (median (1st ;3rd quartiles)) 20 (16,25) 
ICU admission diagnosis category N (%) 
Respiratory  
Cardiovascular 
Gastrointestinal 
Neurological 
Trauma 
Renal diagnosis 
Miscellaneous diagnoses 
 
84 (35) 
70 (29) 
59 (25) 
12 (5) 
8 (3) 
4 (2) 
3 (1) 
Well-nourished N (%) 107 (45) 
Moderately malnourished N (%) 105 (43) 
Severely malnourished N (%) 28 (12) 
Ward destination N (%):       Medical 
                                             Surgical 
135 (56) 
105 (44)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Kendall’s tau  p 
CRP 1 week -0.159 0.018 
3 months -0.026 0.676 
IL-6 1 week -0.122 0.271 
3 months 0.008 0.897 
 
